Scarica l'app Stockscreener
1,131.42
0.55%
6.15
Dopo l'orario di chiusura:
1123.00
-8.42
-0.74%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,125.27
Aprire:
$1142.97
Volume 24 ore:
4.08M
Relative Volume:
1.32
Capitalizzazione di mercato:
$1.01T
Reddito:
$72.25B
Utile/perdita netta:
$25.28B
Rapporto P/E:
40.73
EPS:
27.781
Flusso di cassa netto:
$10.37B
1 W Prestazione:
+2.39%
1M Prestazione:
+14.42%
6M Prestazione:
+11.99%
1 anno Prestazione:
+47.77%
Intervallo 1D:
$1,131.03
$1,166.29
Intervallo di 1 settimana:
$1,052.15
$1,166.29
Portata 52W:
$623.78
$1,166.29
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Downgrade | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Assessing Camurus (OM:CAMX) Valuation After Expanded Eli Lilly Collaboration On FluidCrystal Technology - simplywall.st
What's Keeping Eli Lilly and Company In The Healthcare Spotlight? - Kalkine Media
Deal Watch: Lilly Continues Hectic Deal Stretch Via Renal-Focused Ascidian Collab - Citeline News & Insights
Eli Lilly and Novo Nordisk looking beyond US for obesity drug growth - Business Standard
Here’s Why Eli Lilly (LLY) is Among the 10 Best American Stocks to Buy and Hold for the Next Decade - Insider Monkey
Jim Cramer’s Opinion on 13 Stocks Like Eli Lilly and Boeing and Increased AI-Related Spending - Insider Monkey
Why is Eli Lilly stock rallying today? By Investing.com - Investing.com Nigeria
GLP-1 Drugs Projected to Reach $150B in Sales by 2030, Boosting LLY and NVO - GuruFocus
Eli Lilly and Co Stock (LLY) Moved Up by 3.15% on Jun 5: Facts Behind the Movement - TradingKey
Jim Cramer Details How Eli Lilly Could Defeat Competitors - Yahoo Finance
Eli Lilly (LLY) Stock Surges 4% After CVS Reverses Zepbound Coverage Decision - Blockonomi
Eli Lilly tops list of Ireland’s biggest corporate taxpayers - Business Post
Morgan Stanley reiterates Overweight on Eli Lilly stock, sees upside By Investing.com - Investing.com India
Morgan Stanley reiterates Overweight on Eli Lilly stock, sees upside - Investing.com
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - 富途牛牛
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors - AOL.com
The Zacks Analyst Blog Highlights Berkshire, Eli Lilly, Walmart, Universal Health Realty Income and Utah - Yahoo Finance Singapore
AriBio joins Lilly TuneLab to advance AI-driven neuroscience research - koreabiomed.com
HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWatchers Turn Up The Heat - Stocktwits
Lilly and Novo Now Look Beyond US for Obesity Drug Growth - Bloomberg.com
Lilly and Novo now look beyond US for obesity drug growth - BusinessLine
Eli Lilly and Co (LLY) Shares Surge 4.3% -- What GF Score of 98 Tells Investors - GuruFocus
Analyst Ratings | Citi: Reiterates “Buy” rating on Eli Lilly and Co, saying market concerns over side effects of experimental weight-loss drug are "overblown" - 富途牛牛
Upper Macungie advances Eli Lilly plan - WFMZ.com
Eli Lilly's 'Overbroad' Weight Drug TM Deal Rejected - Law360
Gilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN
Aribio joins Lilly TuneLab to boost AI-driven CNS drug developmentCHOSUNBIZ - Chosunbiz
Aribio Joins Lilly's AI Drug Discovery Platform - 아시아경제
Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits
Eli Lilly, IBD stock of the day, flashes two buy signals - MSN
Eli Lilly, IBD Stock Of The Day, Flashes Two Buy Signals - Investor's Business Daily
Top Analyst Reports for Berkshire Hathaway, Eli Lilly & Walmart - Yahoo Finance
Jim Cramer’s 5 Stock Calls, Including Alphabet and Eli Lilly, and Possible Opportunities - Insider Monkey
Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday - The Motley Fool
Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease TherapiesEli Lilly (NYSE - Benzinga
Lilly Gateway Labs incubator in Center City gets its first tenant - The Business Journals
Why is Eli Lilly stock surging today? - Investing.com
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success - The Motley Fool
Eli Lilly and Co Stock (LLY) Moved Up by 3.56% on Jun 4: What Signal Does It Send? - TradingKey
Eli Lilly's $1 Trillion Milestone and Growth Strategy in 2026News and Statistics - IndexBox
Pharma's New Playbook: How Lilly and Sesame Are Bypassing Insurance - BriefGlance
Weight Watchers connects with Eli Lilly’s LillyDirect platform - Investing.com
3 Reasons Eli Lilly Remains a Buy - The Motley Fool
US pharma giant Eli Lilly is very unhappy with Germany; CEO calls its planned healthcare reform: Terrible - The Times of India
Eli Lilly, Dixie Cup developers are among those seeking tax benefits in Lehigh Valley. Here’s why. - The Morning Call
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup - Forbes
Forget Weight Loss Drugs: Here Is Another Reason to Buy Eli Lilly Stock - The Motley Fool
Eli Lilly (LLY) Stock Analysis: Diversification Strategy and Vaccine Deals in 2026News and Statistics - IndexBox
Moderna Outshines Pharma Giants Lilly, Merck and Pfizer With 43% Year-to-Date Surge - NAI500
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating - 富途牛牛
Eli Lilly Weight Loss Boom Reshapes Healthcare Growth Story - Kalkine Media
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):